Two studies on ALS published by GeNeuro in Annals of Neurology

• The first publication confirms the neurotoxic role of HERV-K/HML-2 ENV detected in the cerebrospinal fluid of sporadic ALS patients and the preclinical therapeutic effect of GeNeuro’s anti-HERV-K ENV antibody in neutralizing HERV-K/HML-2 ENV toxicity.

• The second publication provides a clinically based rationale for the therapeutic use of a specific neutralizing antibody addressing sporadic ALS neuropathology, by demonstrating the positive role of HERV-K ENV-specific but low-abundant natural autoantibodies on the duration of patients’ survival.

• Sporadic ALS is a devastating disease affecting 10,000 new patients per year in the U.S. and Europe, with a very limited survival prognosis.

Read the press release